This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
by Zacks Equity Research
Here is how Brookdale Senior Living (BKD) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vivos Therapeutics, Inc. (VVOS) delivered earnings and revenue surprises of -17.65% and 3.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -41.94% and 28.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -9.52% and 10.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 51.35% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Stocks to Consider with Earnings Approaching
by Shaun Pruitt
As we progress through earnings season several top-rated Zacks stocks are expected to report their first quarter results on Monday, April 24.
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -34.86% and 1.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.